Morgan Stanley Kinnate Biopharma Inc. Transaction History

Morgan Stanley

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$2.24 - $2.66 $16,636 - $19,755	7,427 New	7,427 $19,000
Q1 2024 Aug 16, 2024	BUY	$2.24 - $2.66 $3,823 - $4,540	1,707 Added 29.84%	7,427 $19,000
Q1 2024 May 15, 2024	BUY	$2.24 - $2.66 $3,823 - $4,540	1,707 Added 29.84%	7,427 $19,000
Q4 2023 Aug 16, 2024	BUY	$1.07 - $2.5 $6,120 - $14,300	5,720 New	5,720 $13,000
Q4 2023 Feb 13, 2024	SELL	$1.07 - $2.5 $18,637 - $43,545	-17,418 Reduced 75.28%	5,720 $13,000
Q3 2023 Nov 15, 2023	SELL	$1.38 - $3.31 $94,064 - $225,619	-68,163 Reduced 74.66%	23,138 $32,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $118,077 - $346,630	50,677 Added 124.75%	91,301 $276,000
Q1 2023 May 15, 2023	BUY	$3.46 - $7.98 $62,632 - $144,453	18,102 Added 80.37%	40,624 $253,000
Q4 2022 Feb 14, 2023	SELL	$5.26 - $12.19 $109,355 - $253,430	-20,790 Reduced 48.0%	22,522 $137,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $114,632 - $183,225	-11,626 Reduced 21.16%	43,312 $518,000
Q2 2022 Oct 27, 2022	BUY	$7.43 - $13.0 $120,715 - $211,211	16,247 Added 41.99%	54,938 $693,000
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $120,715 - $211,211	16,247 Added 41.99%	54,938 $693,000
Q1 2022 Oct 27, 2022	SELL	$7.73 - $17.99 $125,589 - $292,283	-16,247 Reduced 29.57%	38,691 $434,000
Q1 2022 May 13, 2022	BUY	$7.73 - $17.99 $23,939 - $55,715	3,097 Added 8.7%	38,691 $434,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $6.06 Million - $9.36 Million	-367,281 Reduced 91.17%	35,594 $631,000
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $7.18 Million - $10 Million	402,875 New	402,875 $9.27 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.